# Prognostic Hypotheses: Time-to-Dementia in Cognitively Impaired Individuals
---
## Hypothesis 1: Executive Dysfunction as Independent Clinical Marker
**Title:** Baseline Executive Function Deficits Predict Faster Dementia Progression via Prefrontal-Subcortical Circuit Disruption
**Description:** Impaired executive function (EF) at baseline independently accelerates dementia onset in MCI beyond memory deficits. The mechanism involves disruption of frontostriatal circuits governing attentional control and behavioral regulation—these networks are particularly vulnerable to small vessel disease and α-synuclein pathology, which bypass hippocampal mechanisms. EF deficits signal a distinct neuropathological substrate with faster progression.
**Target:** N/A (clinical marker)
**Confidence:** 0.75 | Evidence: EF deficits in MCI predict 2-3x faster progression (Banks et al., 2016; Jheng et al., 2022)
---
## Hypothesis 2: APOE ε4 Genotype as Genetic Accelerator of Amyloid-Dependent Decline
**Title:** APOE ε4 Carriage Shortens Dementia-Free Survival Through Enhanced Cortical Aβ Deposition and Synaptic Vulnerability
**Description:** APOE ε4 independently accelerates time-to-dementia in cognitively impaired individuals via cell-autonomous effects on Aβ aggregation, microglial activation, and synaptic repair. ε4 carriers show 2-3x greater amyloid burden and faster spreading from limbic to isocortical regions, compressing the detectable prodromal window. This operates independently of baseline cognition.
**Target:** APOE protein (lipid transport, Aβ binding)
**Confidence:** 0.88 | Evidence: Strong meta-analytic data; Rotterdam Study, ADNI cohort
---
## Hypothesis 3: CSF Neurofilament Light Chain Reflects Neuroaxonal Injury Velocity
**Title:** Elevated CSF NfL Quantifies Active Neurodegeneration Velocity Predicting Imminent Dementia
**Description:** CSF NfL independently predicts dementia onset within 2-3 years in MCI by quantifying the rate of axonal injury independent of amyloid/tau burden. NfL elevation reflects ongoing neuronal loss from any cause (vascular, TDP-43, co-pathology), capturing the "second hit" necessary for clinical conversion. Higher NfL = faster neurodegeneration trajectory.
**Target:** Neurofilament light chain (NfL)
**Confidence:** 0.80 | Evidence: Mattsson et al., 2019; Bairakti et al., 2023
---
## Hypothesis 4: Hippocampal Atrophy Rate Captures Neurodegeneration Stage and Modifies Genetic Risk
**Title:** Accelerated Hippocampal Volume Loss Over 12 Months Is the Strongest Independent Predictor of Conversion Independent of Biomarker Status
**Description:** Annualized hippocampal atrophy rate independently predicts dementia conversion by reflecting the downstream consequence of accumulated pathology (Aβ, tau, vascular). It captures individual-specific progression velocity and modifies APOE ε4 risk—ε4 carriers with rapid atrophy convert 4x faster than ε4 carriers with stable atrophy. This imaging marker integrates multiple pathogenic processes.
**Target:** N/A (imaging marker, downstream endpoint)
**Confidence:** 0.82 | Evidence: Jack et al., 2013; Desikan et al.; longitudinal ADNI/Memory Clinic cohorts
---
**Summary Table**
| Hypothesis | Type | Target | Confidence |
|---|---|---|---|
| Executive dysfunction | Clinical | — | 0.75 |
| APOE ε4 | Genetic | APOE | 0.88 |
| CSF NfL | Biomarker | NfL | 0.80 |
| Hippocampal atrophy | Imaging | — | 0.82 |
**Integration Note:** These markers likely capture distinct mechanistic layers—pathology (APOE), injury velocity (NfL), network failure (EF), and downstream neurodegeneration (hippocampal volume)—making them complementary in a multivariate prognostic model.